JP2016504362A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504362A5 JP2016504362A5 JP2015550675A JP2015550675A JP2016504362A5 JP 2016504362 A5 JP2016504362 A5 JP 2016504362A5 JP 2015550675 A JP2015550675 A JP 2015550675A JP 2015550675 A JP2015550675 A JP 2015550675A JP 2016504362 A5 JP2016504362 A5 JP 2016504362A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- albumin
- composition according
- item
- substantially free
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 65
- 102000009027 Albumins Human genes 0.000 claims description 34
- 108010088751 Albumins Proteins 0.000 claims description 34
- 239000002105 nanoparticle Substances 0.000 claims description 8
- 229930012538 Paclitaxel Natural products 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229960001592 paclitaxel Drugs 0.000 claims description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 6
- 230000013595 glycosylation Effects 0.000 claims description 4
- 238000006206 glycosylation reaction Methods 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 4
- DVUFTQLHHHJEMK-IMJSIDKUSA-N Asp-Ala Chemical group OC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O DVUFTQLHHHJEMK-IMJSIDKUSA-N 0.000 claims description 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 239000012503 blood component Substances 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 238000000034 method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261747123P | 2012-12-28 | 2012-12-28 | |
| US61/747,123 | 2012-12-28 | ||
| US13/794,705 | 2013-03-11 | ||
| US13/794,705 US20140186447A1 (en) | 2012-12-28 | 2013-03-11 | Nanoparticle compositions of albumin and paclitaxel |
| PCT/US2013/076630 WO2014105644A1 (en) | 2012-12-28 | 2013-12-19 | Nanoparticle compositions of albumin and paclitaxel |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018030637A Division JP2018087241A (ja) | 2012-12-28 | 2018-02-23 | アルブミンおよびパクリタキセルのナノ粒子組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016504362A JP2016504362A (ja) | 2016-02-12 |
| JP2016504362A5 true JP2016504362A5 (enExample) | 2017-02-02 |
Family
ID=51017455
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015550675A Pending JP2016504362A (ja) | 2012-12-28 | 2013-12-19 | アルブミンおよびパクリタキセルのナノ粒子組成物 |
| JP2018030637A Pending JP2018087241A (ja) | 2012-12-28 | 2018-02-23 | アルブミンおよびパクリタキセルのナノ粒子組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018030637A Pending JP2018087241A (ja) | 2012-12-28 | 2018-02-23 | アルブミンおよびパクリタキセルのナノ粒子組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20140186447A1 (enExample) |
| EP (1) | EP2938340A4 (enExample) |
| JP (2) | JP2016504362A (enExample) |
| KR (1) | KR20150100903A (enExample) |
| CN (1) | CN105007912A (enExample) |
| AU (1) | AU2013370955B2 (enExample) |
| BR (1) | BR112015015319A2 (enExample) |
| CA (1) | CA2896288A1 (enExample) |
| CR (1) | CR20150386A (enExample) |
| HK (1) | HK1216611A1 (enExample) |
| IL (1) | IL239593A0 (enExample) |
| MX (1) | MX2015008361A (enExample) |
| NI (1) | NI201500090A (enExample) |
| NZ (1) | NZ630912A (enExample) |
| PH (1) | PH12015501486B1 (enExample) |
| RU (1) | RU2663687C2 (enExample) |
| SG (1) | SG11201505111TA (enExample) |
| WO (1) | WO2014105644A1 (enExample) |
| ZA (1) | ZA201504762B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| TWI417114B (zh) | 2005-08-31 | 2013-12-01 | Abraxis Bioscience Llc | 具有增強穩定性之弱水溶性藥物之組合物及其製備方法 |
| CA2672618C (en) | 2006-12-14 | 2021-03-02 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| DK2155188T3 (da) * | 2007-06-01 | 2013-11-04 | Abraxis Bioscience Llc | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft |
| CN102460167B (zh) | 2009-04-15 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 不含朊病毒的纳米颗粒组合物和方法 |
| ES2580135T3 (es) | 2010-03-26 | 2016-08-19 | Abraxis Bioscience, Llc | Métodos de tratamiento de carcinoma hepatocelular |
| AU2011232862B2 (en) | 2010-03-29 | 2016-03-03 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| NZ628423A (en) | 2010-03-29 | 2016-03-31 | Abraxis Bioscience Llc | Methods of treating cancer |
| RU2576609C2 (ru) | 2010-06-04 | 2016-03-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечение рака поджелудочной железы |
| CA3063641A1 (en) | 2011-04-28 | 2012-11-01 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| PT2707030T (pt) | 2011-05-09 | 2020-05-22 | Mayo Found Medical Education & Res | Tratamentos de cancro |
| DK2790675T3 (da) | 2011-12-14 | 2019-09-09 | Abraxis Bioscience Llc | Anvendelse af polymerexcipienser til frysetørring eller frysning af partikler |
| US10413606B2 (en) | 2012-10-01 | 2019-09-17 | Mayo Foundation For Medical Education And Research | Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| NZ630392A (en) | 2013-03-12 | 2016-10-28 | Abraxis Bioscience Llc | Methods of treating lung cancer |
| RU2015143490A (ru) | 2013-03-14 | 2017-04-26 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения рака мочевого пузыря |
| WO2014191569A1 (en) | 2013-05-30 | 2014-12-04 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| JP6695286B2 (ja) | 2014-06-13 | 2020-05-20 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | リンパ腫の処置 |
| KR20170020371A (ko) | 2014-06-16 | 2017-02-22 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 골수종의 치료 |
| CN104224750A (zh) * | 2014-09-17 | 2014-12-24 | 四川大学 | 一种注射用卡巴他赛白蛋白纳米粒制剂及其制备方法 |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| TW201628644A (zh) * | 2014-11-25 | 2016-08-16 | 奈諾生技公司 | 醫藥組合物、其製備及其用途 |
| US10765632B2 (en) | 2014-11-25 | 2020-09-08 | Curadigm Sas | Methods of improving delivery of compounds for therapy, prophylaxis or diagnosis |
| PT3229776T (pt) | 2014-11-25 | 2023-08-17 | Curadigm Sas | Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações |
| AR102780A1 (es) | 2014-11-25 | 2017-03-22 | Nanobiotix | Composiciones farmacéuticas, su preparación y sus usos |
| US10527604B1 (en) * | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| MA43100A (fr) | 2015-05-28 | 2018-09-05 | Nanobiotix | Nanoparticules à utiliser en tant que vaccin thérapeutique |
| HUE070408T2 (hu) | 2015-06-29 | 2025-06-28 | Abraxis Bioscience Llc | Szirolimuszt és albumint tartalmazó nanorészecskék epitelioid sejtes tumorok kezelésében történõ alkalmazásra |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
| CA3014531A1 (en) | 2016-02-12 | 2017-08-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| WO2017165439A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| EP3432926A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | METHOD FOR REDUCING THE TOXICITY OF CHEMOTHERAPEUTICS |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| AU2017321798B2 (en) | 2016-09-01 | 2023-06-15 | Mayo Foundation For Medical Education And Research | Methods and compositions for targeting T-cell cancers |
| MX2019002474A (es) | 2016-09-01 | 2019-09-18 | Mayo Found Medical Education & Res | Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres. |
| RU2756892C2 (ru) | 2016-09-06 | 2021-10-06 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения |
| EP3509635A1 (en) | 2016-09-06 | 2019-07-17 | Vavotar Life Sciences LLC | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| WO2018048816A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Methods of treating pd-l1 expressing cancer |
| CN106420665B (zh) * | 2016-10-28 | 2019-04-16 | 浙江省林业科学研究院 | 一种包裹紫杉烷类药物的白蛋白纳米颗粒载体的制备方法 |
| RU2020110399A (ru) | 2017-10-03 | 2021-11-09 | Крититек, Инк. | Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака |
| WO2019183146A1 (en) | 2018-03-20 | 2019-09-26 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| US20220401374A1 (en) * | 2019-09-13 | 2022-12-22 | Purdue Research Foundation | Compositions and methods for cancer treatment by enhancing antitumor immunity using tannic acid-based nanocapsules |
| JP2022553426A (ja) * | 2019-10-28 | 2022-12-22 | アブラクシス バイオサイエンス， エルエルシー | アルブミンおよびラパマイシンの医薬組成物 |
| KR20220113699A (ko) * | 2019-11-11 | 2022-08-16 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물에 대한 바이오마커 |
| WO2021158937A1 (en) * | 2020-02-05 | 2021-08-12 | The Johns Hopkins University | Bortezomib-loaded nanoparticles |
| KR102526793B1 (ko) * | 2021-11-03 | 2023-04-28 | 주식회사 에스엔바이오사이언스 | 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법 |
| WO2024118542A1 (en) * | 2022-11-28 | 2024-06-06 | Takeda Vaccines, Inc. | A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728553A (en) * | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US6749868B1 (en) * | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| EP1100494A1 (en) * | 1998-07-30 | 2001-05-23 | Novopharm Biotech, Inc. | Pharmaceutically composition comprising an aqueous solution of paclitaxel and albumin |
| JP4798832B2 (ja) * | 2000-10-24 | 2011-10-19 | 一般財団法人化学及血清療法研究所 | ヒト血清アルブミン多量体の除去方法 |
| NZ598588A (en) * | 2009-08-25 | 2014-05-30 | Abraxis Bioscience Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| ES2580135T3 (es) * | 2010-03-26 | 2016-08-19 | Abraxis Bioscience, Llc | Métodos de tratamiento de carcinoma hepatocelular |
| WO2012092712A1 (zh) * | 2011-01-07 | 2012-07-12 | 无锡圆容生物医药股份有限公司 | 一种含有重组人血白蛋白的纳米颗粒冷冻干燥粉末制剂 |
| CN102078306A (zh) * | 2011-01-11 | 2011-06-01 | 无锡圆容生物医药股份有限公司 | 一种含有重组人血白蛋白的紫杉醇纳米颗粒冷冻干燥制剂 |
-
2013
- 2013-03-11 US US13/794,705 patent/US20140186447A1/en not_active Abandoned
- 2013-12-19 CN CN201380073926.7A patent/CN105007912A/zh active Pending
- 2013-12-19 KR KR1020157020337A patent/KR20150100903A/ko not_active Withdrawn
- 2013-12-19 NZ NZ630912A patent/NZ630912A/en unknown
- 2013-12-19 SG SG11201505111TA patent/SG11201505111TA/en unknown
- 2013-12-19 WO PCT/US2013/076630 patent/WO2014105644A1/en not_active Ceased
- 2013-12-19 BR BR112015015319A patent/BR112015015319A2/pt not_active Application Discontinuation
- 2013-12-19 MX MX2015008361A patent/MX2015008361A/es unknown
- 2013-12-19 AU AU2013370955A patent/AU2013370955B2/en active Active
- 2013-12-19 JP JP2015550675A patent/JP2016504362A/ja active Pending
- 2013-12-19 RU RU2015131141A patent/RU2663687C2/ru active
- 2013-12-19 CA CA2896288A patent/CA2896288A1/en not_active Abandoned
- 2013-12-19 HK HK16104504.3A patent/HK1216611A1/zh unknown
- 2013-12-19 EP EP13868481.6A patent/EP2938340A4/en not_active Withdrawn
-
2015
- 2015-06-23 IL IL239593A patent/IL239593A0/en unknown
- 2015-06-26 NI NI201500090A patent/NI201500090A/es unknown
- 2015-06-26 PH PH12015501486A patent/PH12015501486B1/en unknown
- 2015-07-02 ZA ZA2015/04762A patent/ZA201504762B/en unknown
- 2015-07-22 CR CR20150386A patent/CR20150386A/es unknown
-
2018
- 2018-02-23 JP JP2018030637A patent/JP2018087241A/ja active Pending
- 2018-10-25 US US16/170,522 patent/US20190192477A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016504362A5 (enExample) | ||
| RU2015131141A (ru) | Композиции наночастиц альбумина и паклитаксела | |
| AT515178A5 (de) | Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie | |
| JP2016513075A5 (enExample) | ||
| JP2012520323A5 (enExample) | ||
| BR112012024590A2 (pt) | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos | |
| JP2016512513A5 (enExample) | ||
| MX2019005287A (es) | Lipidos cationicos para suministro de acido nucleico y su preparacion. | |
| Thomas et al. | Intracellular delivery of doxorubicin encapsulated in novel pH-responsive chitosan/heparin nanocapsules | |
| NO20080202L (no) | Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer | |
| AR095456A1 (es) | Composiciones de dos componentes que contienen complejos de halogenuro de cinc y aminoácido y cisteína | |
| WO2015018380A3 (en) | Therapeutic nanoparticles and the preparation methods thereof | |
| JP2017517556A5 (enExample) | ||
| BR112019007087A2 (pt) | formulações de nanopartículas e métodos de fabricação e de utilização das mesmas | |
| MX2016000019A (es) | (arnip) gen especifico relacionado con las enfermedades respiratorias, (arnip) que contiene la estructura arn oligo helicoidal, composicion que contiene la misma para prevencion o tratamiento de las enfermedades respiratorias. | |
| BR112015019039A8 (pt) | compostos antagonistas de integrina fluorados, composição farmacêutica compreendendo ditos compostos e uso destes para tratar ou prevenir uma doença ou condição mediada por uma av integrina | |
| WO2015152693A3 (ko) | 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물 | |
| CN108026053A8 (zh) | 作为mIDH1抑制剂的稠合的咪唑类化合物 | |
| WO2017017063A3 (en) | Nanoparticle-based liver-targeting therapy and imaging | |
| EA201791537A1 (ru) | Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение | |
| JP2016510326A5 (enExample) | ||
| JP2014505702A5 (enExample) | ||
| JP2015502926A5 (enExample) | ||
| MX388073B (es) | Composición farmacéutica, preparación y usos de la misma. | |
| WO2018229093A8 (en) | NANOPARTICLES AS DELIVERY VEHICLES OF ACTIVE PRINCIPLES AND METHODS OF PRODUCING SAME |